Imaging in clinical oncology trials provides a wealth of information that contributes to the drug development process, especially in early phase studies. This paper focuses on kinetic modeling in DCE-MRI, where the subjects were imaged before and after two cycles of chemotherapy, demonstrating the clinical potential of this method to longitudinal oncology studies.
zero (11) . The fixed effects in the model explain as much variance as possible, whereas the random effects capture variability that cannot be explained by the fixed effects.
Formulation of a Bayesian hierarchical model is typically achieved in three stages: the data model, the parameter model and the prior distributions (12; 13) . The data model reflects our knowledge of the CTCs at the voxel level using the class of compartmental models (14; 15; 16) with a standard arterial input function (AIF) taken from the literature (17; 18; 19) . The parameter model describes how parameters R1.1 from the compartmental model are associated with important factors of the clinical trial. At this stage we decompose the kinetic parameters into treatment, patient and voxel effects. We acknowledge that this decomposition will depend on the specific features unique to the clinical trial design. Following from Bayesian theory all parameters are regarded as random variables with pre-specified (prior) distributions.
This includes the parameters for the fixed as well as the random effects in the model. Choices have been made in the construction of the Bayesian hierarchical model in order to utilize efficient sampling methods wherever possible, and therefore reduce the computational burden.
The output from the Bayesian hierarchical model not only answers the basic question from a DCE-MRI oncology study (i.e., did the treatment reduce K trans ?) but also provides information about various aspects of the study through the decomposition of the kinetic parameters. Posterior estimates for K trans and k ep are available to inspect the treatment effect for each subject, averaged over the tumor region of interest, for potential comparison with clinical endpoints. Estimates at the voxel level are also available which allow one to separate spatial heterogeneity within a single region of interest with uncertainty in the kinetic parameters due to a poor model fit. Estimates at the patient level may be used to compare imaging biomarkers (kinetic parameters) with clinical endpoints, such as clinical response or clinical benefit. The breast cancer study analyzed here illustrates the potential of this methodology by interrogating the output from the hierarchical model at several levels.
Bayesian Hierarchical Model
Bayesian methods rely on the specification of prior distributions p(θ), that express our information about the unknown parameters θ before any measurements are taken, and combine this information with empirical evidence from direct observations in order to estimate those parameters. To assess the model parameters after observing the data, the posterior distribution p(θ | Y) is computed, where θ is the vector of all unknown parameters and Y is the vector of observations. The posterior distribution of the parameter vector θ is obtained by applying Bayes' theorem
where ℓ(Y | θ) denotes the likelihood function of Y and p(θ) the product of all a priori probability distribution functions. One can think of the posterior as an update to the prior distribution, our beliefs, on θ after measuring a process -producing a mixture of previous knowledge and experimental data.
Examples of such Bayesian methodology in neuroimaging exists for functional MRI (20; 21) and also diffusion tensor imaging (22) .
The following sections introduce the key components in the Bayesian hierarchical model: the data model, the parameter model and the prior distributions. Each stage of the model development has been tailored to the analysis of a longitudinal cancer treatment study with two time points. Figure 1 provides a schematic overview of the proposed Bayesian Hierarchical Model (BHM). The three model stages are the rows and the columns represent the "resolution" of the parameters. The kinetic parameters of interest K trans and k ep are decomposed into global (study-wide), subject and voxel effects through the BHM, while v p is simply estimated for each voxel without further decomposition. The measurement error term is independent of the specific parameter model and involves both prior and hyperprior distributions. A standard compartmental model is used to describe the concentration time curves observed at each voxel.
A generalized additive model (23) is proposed to decompose the kinetic parameters into factors that are relevant to the design of the longitudinal study. Finally, the prior distributions, including necessary hyperparameters, are specified on all factors of the parameter model (these terms will be explained in detail subsequently). These prior distributions are relatively flat, reflecting a lack of knowledge concerning the parameter, but also incorporate biological knowledge, such as a transfer rate must be non-negative, or statistical knowledge, for example a variance must be non-negative.
Data Model
A hierarchical Bayesian framework is used to model the contrast agent concentration time curve (CTC) of all voxels (24) .
T denote the CTC associated with a single voxel observed at T time points determined by the image acquisition protocol. The CTC is assumed to follow a standard compartment model (19)
where ⊗ denotes the convolution operator, K trans represents the transfer rate from plasma to extracellular extravascular space (EES) per minute, k ep the rate constant between EES and blood plasma per minute and v p the vascular space fraction. The choice of model for the CTC depends on the scientific goals of the study. Replacing Eq.
[2] with a more or less complicated model is straightforward in our model-building R1.2
framework. The vector of observations Y may therefore be thought of as noisy measurements of the true contrast agent concentration C t (t), sampled at the discrete values t 1 , t 2 , . . . , t T to produce the vector
T , given as a realization of a multivariate Normal distribution
where the notation Y ∼ N T (µ, Σ) means that the random variable Y comes from a multivariate Normal distribution of dimension T with a mean vector µ and covariance matrix Σ.
We assume a common arterial input function (AIF), taken from the literature for all patients in the study, and use a bi-exponential function (15) 
Parameter Model
The pharmacokinetic parameters from the data model are defined at every tumor voxel across all subjects and scans. We assume a priori that the distribution of the random variables K trans and k ep in the tumor are patient-specific and are changed by treatment in a similar way. Therefore a generalized additive model is used where the log-transformed kinetic parameters ψ 1 = ln(K trans ) and ψ 2 = ln(k ep ) are expressed as a linear combination of fixed-and random-effects associated with identifiable factors in the study.
In addition to restricting both parameters to be positive, the log transform is appealing in this context because individual terms in the additive model may be interpreted as a percentage change from baseline.
We assume that the distribution of the vascular fraction v p will not be modified by the treatment, but individual v p values are allowed to change at the voxel level. Let i = 1, . . . , I denote the scans acquired and let j = 1, . . . , J denote the patients, so that n ij denotes the number of tumor voxels for patient j at scan i, measured at T time points.
The factor of interest when measuring a change in the kinetic parameters (K trans or k ep ) is the treatment effect, or the difference between pre-and post-treatment visits in the study investigated here.
It is necessary to model the fact that substantial variability exists across patients in the study and between the voxels in each region of interest (ROI) that describes the enhancing region in the dynamic acquisition.
Hence, the model for ln(K trans ) is given by
where k denotes a unique voxel in the tumor ROI and
The parameter α 1 is the factor of ln(K trans ) associated with the baseline scan and β 1 is the treatment effect (since it is only associated with the post-treatment acquisition). For the clinical study analyzed here, the treatment effect for K trans , as quantified via β 1 , is the key parameter of interest. A formal hypothesis test will be performed on β 1 in order to detect a significant reduction in K trans between the pre-and post-treatment scans.
The parameters α 1 and β 1 are regarded as fixed effects (the global column of Figure 1 ), and thus do not vary between patients in the study. In the Bayesian framework, a marginal posterior distribution will be available for each parameter. The parameter γ j1 is the effect of patient j on ln(K trans ) and δ j1 is the interaction between patient j and treatment. Although the parameters α 1 and β 1 summarize information for the baseline and treatment effects of K trans across all subjects in the study, the parameters γ j1 and δ j1 allow the estimate of K trans to adapt to the baseline and treatment effects observed for each subject.
These parameters are random effects since each patient is assumed to be drawn from a larger population of patients suffering from this condition (the subject column of Figure 1 ). Finally, the parameter ϵ ijk1 is the random effect of voxel k in scan i of patient j on ln(K trans ). The voxel effect models the fact that each voxel in the tumor volume is drawn from a distribution that describes the ideal tumor voxel (the voxel column of Figure 1 ). The combination of fixed and random effects in a single model is commonly referred to as a mixed-effects model (9) .
Using matrix notation, we can combine the generalized additive model across both kinetic parameters, ln K trans and ln k ep , such that
The scan-specific covariates in the model are captured in Z i , the fixed effects are in φ, the patientspecific random effects are in θ j and the voxel-specific random effects are in ϵ ijk . The model formulation in Eq. [7] can be adapted in order to incorporate additional covariates or a greater number of scans (e.g., in a longitudinal study).
Prior Distributions
In the Bayesian framework prior distributions with unknown variances are used to model the ran-R1. 3 dom effects (26) . We use vector notation to denote the patient-specific random effects such that γ = 
where τ 2 γ and τ 2 δ are vectors of the same length and indexed as γ and δ, respectively. The voxel-specific random-effect vectors are given unique prior distributions by scan, patient and parameter, so that each vector is given by
T . We use a multivariate Gaussian prior distribution
where n ij is the number of voxels in the region of interest of scan i of patient j, and τ 2 ϵ;ijl is an unknown variance associated with scan i, patient j and kinetic parameter l. Since the variances are unknown parameters, they must have their own prior distributions which are given by
where a = b = c = 1, d = 10 −5 , and IG(·, ·) denotes the inverse Gamma distribution (27) . Note, the notation X iid ∼ F means that all random variables X i in the vector X are independently and identically distributed from the distribution F . The inverse Gamma distribution is known as a conjugate prior for the Normal distribution (12); i.e., the posterior distribution of γ given the variance τ 2 γ and all other parameters (known as the full conditional distribution) is again a multivariate Gaussian distribution (see the Appendix for further details). For the fixed effects we use uniform priors so that the prior distribution does not contain any relevant information, denoted by
Note, the prior distributions on α and β are improper (not a valid probability distribution), but this is not a problem since the full conditional distributions for both parameters are valid distributions (see the Appendix).
The prior distributions on the coefficients in the generalized additive model have been chosen so that as much variance in the data as possible is explained by the fixed effects α and β -as no prior information is used for those parameters. Variability which cannot be explained by the fixed effects will be covered by the random effects γ and δ. For these parameters an additional prior distribution (hyperprior) on the variance of the parameters is defined which leads to a shrinkage of those effects; that is, the parameters are pushed towards zero and therefore do not cover variance explained by the fixed effects. Any additional variance is explained by the voxel effects. Fig. 2 shows the prior probability density function for the patient-specific effects, exp(γ) and exp(δ), and for the voxel effect exp(ϵ). The figure shows that the R1.7
prior distribution on the voxel effects is quite informative and does a priori not allow the voxel effect to deviate much from baseline and patient specific effect. The patient-specific effects are less informative, being stochastically restricted to the typical range of values for K trans and k ep in breast cancer (28; 25) .
The prior probability density function of α and β however can not be drawn, as both priors are uniform.
It is worth noting, that the prior distribution of ψ is also flat; i.e., there is no prior information on log(K trans ) and log(k ep ).
For the vascular space fraction we impose a relatively flat prior
with e = 1 and f = 19, where B(e, f ) denotes the Beta distribution (29) , so that the a priori expected value of v p is e/(e + f ) = 0.05. The Bayesian hierarchical model is complete by specifying a prior distribution for the variance of the observational error in Eq. [3] , with one variance parameter per scan per patient,
where g = 1 and h = 10 −2 . Note, the prior specification depends on the patient and scanning session but is assumed to be the same across voxels.
Materials and Methods

Data acquisition
The first twelve patients from a previously reported breast cancer study are included in the analysis (30; 25) . Data were provided by the Paul Strickland Scanner Centre (PSSC) at Mount Vernon Hospital, Northwood, UK. Each patient underwent a DCE-MRI study before and after two cycles of chemotherapy (5-fluorouracil, epirubicin and cyclophosphamide). Six of these patients were identified as pathological responders after receiving six cycles of chemotherapy, the others were non-responders.
For the calculation of T 1 values, we used a two-point measurement with calibration curves as described in (31; Regions of interest (ROIs) were drawn manually by an expert radiologist on a scan-by-scan basis using anatomical images and subtraction images from the dynamic data to define tumor voxels in preand post-treatment scans.
Parameter Estimation via MCMC
The proposed Bayesian hierarchical model produces a joint posterior distribution of all parameters by combining the data model (also known as the likelihood function), the parameter model and the prior models (also known as the prior distributions), via Bayes theorem, Eq. [1] . Samples from the posterior distribution may be assessed via Markov chain Monte Carlo (MCMC) (34) . Samples from the joint posterior distribution are used to obtain additional information on the accuracy and precision of the estimates.
For example, the standard error of the posterior distribution is the observational error. Statistics of interest (e.g., the mean, median, quantiles, etc.) may be derived from the posterior distribution so that not only point estimates but also confidence intervals are readily available for all parameters.
Implementation of the MCMC algorithm involved 25,000 iterations being drawn from the posterior distribution after an initial burn-in phase. To reduce computer storage, every 10th sample was used, producing a total of 2500 samples to describe the posterior distribution. The sampling rate was determined by visual inspection of the sample autocorrelation function. The burn-in phase involved 10,000 iterations; after this the algorithm was judged to have converged to the invariant distribution and produce samples R1.4 from the posterior distribution that are independent from the initial starting conditions. The length of the burn-in phase was determined by visual inspection of the sampled parameters. The analysis of the R1.11
full study took approximately 48 hours.
The global parameter φ and patient-specific parameters θ j were drawn en bloc in Gaussian Gibbs steps (35) , and hyperparameters were drawn in independent Gamma Gibbs steps (technical details may be found in the Appendix). Metropolis-Hastings steps with random walk proposals were necessary for the voxel-specific random effects and vascular space fraction. The algorithm was tuned to an acceptance rate of 30-50% (36). Summary statistics were computed from the samples of the posterior distribution to provide point estimates of the parameters from the generalized additive model. Empirical standard errors, along with sample quantiles, were used to characterize the precision of the parameter estimates.
Results
All parameter estimates are derived from the posterior distribution using Bayes theorem. Hence, a sampling distribution for each parameter value has been built up from which we produce a point estimate via the median of the sample and also credible intervals (Bayesian confidence intervals) by using the quantiles from their sampling distributions.
How the individual parameters from the generalized additive model coalesce to fit the observed contrast agent concentration time curve is illustrated, at the voxel level, in Figure 3 . The observed CTCs for two voxels from three subjects, one voxel at baseline and one voxel after treatment, are plotted along with three fitted curves. The best estimate from the Bayesian hierarchical model at a specific voxel is provided by the solid lines in each plot. That is, all parameters from the generalized additive model in Eq. [7] are used in the parameter model in order to fit the data model. These curves are very similar to, but not exactly the same as, model fits from the standard non-linear regression method used in the quantitative analysis of DCE-MRI data (25) . Removing the voxel-specific term from the model produces a fitted curve that is associated with patient and treatment effects, but not the specific voxel, and are plotted as dashed lines in Figure 3 . Given the presence of inter-voxel heterogeneity in the tumor ROI, the dashed lines may or may not fit the observed data at a given voxel very well but they do represent the best (in the sense of a posterior median) fit to all voxels in the tumor ROI for a given patient at a The density estimates in Figure 4 are unimodal and indicate an overall decrease in K trans after treatment. In order to test for a treatment effect on K trans , specifically a reduction in K trans in the second acquisition compared to the first, we construct the hypothesis
using the treatment effect from the parameter model in Eq. [7] and calculate the posterior probability of β 1 exceeding zero. From the results of the MCMC simulation, the null hypothesis is rejected with
When the generalized additive model was introduced previously the fact that the parameter K median reduction in K trans which is very similar to the overall treatment effect. This is definitely not the norm as patient 9 experienced a 100% · |0.4285 − 1| = 57.2% median reduction in K trans and patient 6 experienced a 100% · |1.0817 − 1| = 8.17% median increase in K trans , both were pathological responders. slightly wider smoothing kernel could eliminate this apparent feature and produce a broad single peak.
Discussion
Information is obtained at multiple levels during an imaging study in the clinical trial setting. The 
Comparison with Nonlinear Regression
A standard analysis was performed on the ROIs, using nonlinear regression to estimate the kinetic parameters in the compartmental model over all voxels independently, and the median K trans values have been summarized in Table 1 . A non-parametric test (one-sided Wilcoxon signed rank test) was performed to test that the difference between the median values was greater than zero; i.e., the treatment did not reduce K trans across all subjects. The null hypothesis was rejected at a borderline significance level (p = 0.055). Given the small sample size, N 1 = 6 responders and N 2 = 6 non-responders, this is an impressive result and there is obviously a reasonable difference in K trans between the two groups. Fig. 7 shows the kernel density estimates of K trans for each ROI, before and after treatment, using a voxel-wise nonlinear regression analysis. That is, the compartmental model in Eq. [2] was fitted to each voxel independently using the Levenberg-Marquardt optimization procedure. The empirical distributions observed for each patient are extremely similar to those obtained in the BHM, Fig. 6 . This is to be expected given the relatively flat priors that were imposed on the kinetic parameters (25) . The only R1.10 difference between Figs. 6 and 7 is the method of kinetic parameter estimation -Bayesian versus nonlinear regression.
While the voxel-wise results from the Bayesian and regression methods are very similar, and thus provide a check on the consistency of the Bayesian model fitting procedure, the advantages of the Bayesian hierarchical model are clear through the coefficients from the generalized additive model in Eq. [7] . The regression analysis can only summarize the study through Table 1 , but the BHM allows one to isolate and interrogate specific effects, at the study or patient or voxel level, through the generalized additive 
Prior assumptions
Bayesian models rely on a priori beliefs about the model and parameters, expressed as prior distributions.
When combined with observed data, these beliefs are updated to reflect both sources of information. In general, the use of relatively flat (uninformative) prior distributions produces a parameter estimates with similar characteristics to those obtained from maximum-likelihood estimation, and hence similar results overall. In the proposed Bayesian hierarchical model our prior beliefs are based on a mixed-effect model and follow suggestions in the Bayesian mixed-effect literature (26) and in kinetic modelling in DCE-MRI (28; 25). The baseline and treatment effect are modelled as fixed effects, and thus uniform priors are used for those parameters. The patient-specific effects and the voxel-specific effect are modelled as mixed effects, where a Gaussian distribution with zero mean and unknown variance is used. This is also known as shrinkage prior, as it shifts the parameters towards zero. The so-called hyperprior on the unknown variance terms in these prior distributions determines how much variability is accumulated by the fixed effects versus the random effects. Hence, the hyperpriors are chosen so that the baseline and treatment effects explain as much variability as possible. The patient-specific effects accumulate variability not explained by baseline and treatment and the voxel effect accumulates variability not explained by baseline, treatment or the patient-specific effects. The prior on the voxel effects is quite R1.10 informative and ensures that these effects are only used when the fixed effects, and the patient-specific effects, are unable to model the observed concentration time curve; i.e., the information contained in the MR measurements must overcome the relatively strong prior specification. Fig. 8 depicts prior and R1.9
posterior distribution of patient-specific and voxel effects. As previously mentioned the prior distribution on the voxel effects is informative, but the posterior distributions differ substantially from the prior and hence are driven by the observed data. For the patient-specific effects, the prior is less informative and again the information contained in the observed data produce posterior distributions with low variance that differ from the prior. We did not use prior information to impose a specific relationship between K trans and k ep ; e.g., R1.12
From a modelling point of view, the compartmental model is a rough approximation to the physical system that is being investigated via DCE-MRI. At least two layers of abstraction sit between the biological truth and what is measured in DCE-MRI as inferred via a parametric model: the data acquired via MRI are imperfect measurements of the biological system because of the interaction between physics and biology in the measurement process; and the fact that the "extended Kety model" is a gross approximation to the underlying system. Hence, the kinetic parameters obtained from the extended Kety model are relatively far removed from the biological processes and we feel it would be too restrictive to enforce strict relationships between them in the BHM. In the results from the BHM on 12 subjects presented here, we found that K trans was larger than k ep in less than 1.5% of all voxels analyzed. These were typically located at the edge of the tumor ROI, where perfusion characteristics often cause errors in parameter estimation (2) .
The signal intensity in magnitude MR images is known to be Rician, and approximately Gaussian for moderate signal-to-noise values, but the distribution of the error of the contrast agent concentration is a non-linear transformation of the observed signal intensities and, to the best of our knowledge, is not known analytically. However, for positive values of contrast agent concentration in tissue a Gaussian distribution seems appropriate. The hyperprior was determined by sensitivity analysis, and the model was not found to be sensitive to changes in the specification of this hyperprior.
Modifications and Extensions
In this paper a generalized additive model was constructed for the kinetic parameters (K trans and k ep ) in a compartmental model of a DCE-MRI oncology study. The model can easily be modified for other R1.6 kinetic parameters of interest; e.g., if the variable of interest in a study is the volume fraction of the EES (v e = K trans /k ep ) or v p , which was handled as nuisance parameter in the study investigated here. The framework can also be applied to other kinetic models (39; 40) .
This model incorporated two scanning sessions, and all subjects, to asses the treatment effect. The modeling framework is easily extended to handle additional covariates or scanning sessions. For example, a dose-ranging study design could be incorporated into the additive model where the treatment effect can be expressed as a function of the dose. Additional scans over time would enable the assessment of temporal dependence on treatment and provide information about the reliability of the data by potentially reducing the amount of uncertainty in the parameter estimates.
Another possible extension of this model would be to include the spatial information of adjacent voxels.
In the current implementation of the Bayesian hierarchical model all voxels from one region of interest (tumor) were treated as spatially independent. Since voxel borders are arbitrary and do not represent physiological boundaries between different tissue types, it is likely that neighboring voxels share similar perfusion characteristics. This fact has been taken advantage of in the context of Bayesian modeling of individual scans from a DCE-MRI study (25) . The inclusion of a neighborhood structure in the modeling process would reduce the uncertainty in estimation and provide more reliable estimates of the kinetic parameters.
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A Appendix
A.1 Full conditional distributions
In each iteration of the MCMC (Markov chain Monte Carlo) algorithm, a random sample from the marginal posterior distribution for all parameters is drawn. This is performed by sampling from the conditional posterior distribution of one or more parameters given all other parameters and the data.
Hence, the full conditional distributions must be computed. The full conditional is denoted by θ | ·, where θ is the parameter and · denotes all other parameters and the data. If the full conditional takes the from of a standard distribution, one can sample directly form this distribution; this is known as the Gibbs sampler (34) . If the full conditional is not a standard distribution, then a Metropolis-Hastings sampler must be constructed.
In the proposed Bayesian hierarchical model all full conditionals are from standard distributions due to the use of conjugate prior distributions, except for the voxel effect and v p . Let
denote the vector of length P = I(J +1) associated with all parameters in the generalized additive model, except the voxel effect, for a specific kinetic parameter. The full conditional of ξ l is a multivariate Normal distribution given by
where W is a I(J + 1)×P matrix indicating which covariate should be included in the parameter model, Eq. [7] , and Λ is a diagonal matrix with elements n ij τ ϵ;ij . The vector ξ l is drawn in one block from a multivariate Normal distribution with an efficient block-sampling algorithm (41) .
The full conditional distribution of the voxel effect ϵ ijkl is a non-standard distribution. For computational reasons it is more convenient to sample from ψ ijkl rather than from ϵ ijkl , where the full conditional distribution of ψ ijkl is given by
Note, Y ijkl is the estimated contrast agent concentration curve given by the estimated model parameters inψ ijkl . Samples from this distribution are obtained using a Metropolis-Hastings step.
The full conditionals of all variance parameters are inverse Gamma distributions, which are given by
Hence, the variance parameters can be drawn independently using a Gibbs sampler.
Figure Captions At pre-treatment K trans is given by exp(α 1 + γ j1 + ϵ 1jk1 ) for scan 1, patient j and voxel k. At post-treatment K trans is given by exp(α 1 + β 1 + γ 1j + δ 1j + ϵ 12jk ) for scan 2, patient j and voxel k. 8. Prior (bold line) and posterior (thin lines) probability density functions for patient-specific effects R1.9
γ (top) and voxel effects ϵ (bottom). For the voxel-specific effects, 25 random voxels from the pre-treatment scan of patient 2 have been displayed. 
